{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:38:16Z","timestamp":1792431496745,"version":"4.5.0"},"reference-count":291,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"publisher","award":["SUB.D090.22.053"],"award-info":[{"award-number":["SUB.D090.22.053"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Solid cancers are the most common types of cancers diagnosed globally and comprise a large number of deaths each year. The main challenge currently in drug development for tumors raised from solid organs is to find more selective compounds, which exploit specific molecular targets. In this work, the small molecule drugs registered by the Food and Drug Administration (FDA) for solid cancers treatment between 2011 and 2022 were identified and analyzed by investigating a type of therapy they are used for, as well as their structures and mechanisms of action. On average, 4 new small molecule agents were introduced each year, with a few exceptions, for a total of 62 new drug approvals. A total of 50 of all FDA-approved drugs have also been authorized for use in the European Union by the European Medicines Agency (EMA). Our analysis indicates that many more anticancer molecules show a selective mode of action, i.e., 49 targeted agents, 5 hormone therapies and 3 radiopharmaceuticals, compared to less specific cytostatic action, i.e., 5 chemotherapeutic agents. It should be emphasized that new medications are indicated for use mainly for monotherapy and less for a combination or adjuvant therapies. The comprehensive data presented in this review can serve for further design and development of more specific targeted agents in clinical usage for solid tumors.<\/jats:p>","DOI":"10.3390\/molecules27072259","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:34:29Z","timestamp":1648762469000},"page":"2259","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-4277","authenticated-orcid":false,"given":"Aleksandra","family":"Sochacka-\u0106wik\u0142a","sequence":"first","affiliation":[{"name":"Department of Organic Chemistry and Drug Technology, Faculty of Pharmacy, Wroclaw Medical University, 211A Borowska Street, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-344X","authenticated-orcid":false,"given":"Marcin","family":"M\u0105czy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry and Drug Technology, Faculty of Pharmacy, Wroclaw Medical University, 211A Borowska Street, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5806-0001","authenticated-orcid":false,"given":"Andrzej","family":"Regiec","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry and Drug Technology, Faculty of Pharmacy, Wroclaw Medical University, 211A Borowska Street, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3322\/canjclin.54.2.94","article-title":"Soft tissue sarcomas","volume":"54","author":"Cormier","year":"2004","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kramer, I. (2016). Chapter 1\u2014Prologue: Signal Transduction from an Historical Perspective. Signal Transduction, Academic Press. [3rd ed.].","DOI":"10.1016\/B978-0-12-394803-8.00001-2"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e22900","DOI":"10.1002\/jbt.22900","article-title":"The current knowledge concerning solid cancer and therapy","volume":"35","author":"Najafi","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Pottier, C., Fresnais, M., Gilon, M., J\u00e9rusalem, G., Longuesp\u00e9e, R., and Sounni, N.E. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers, 12.","DOI":"10.3390\/cancers12030731"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","article-title":"Tyrosine kinase\u2014Role and significance in Cancer","volume":"1","author":"Paul","year":"2004","journal-title":"Int. J. Med. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clinbiochem.2004.05.006","article-title":"Tyrosine kinase inhibitors in cancer therapy","volume":"37","author":"Madhusudan","year":"2004","journal-title":"Clin. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/01243894-200610000-00003","article-title":"Vascular endothelial growth factor (VEGF) pathway","volume":"1","author":"Nilsson","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13046-019-1094-2","article-title":"Clinical development of targeted and immune based anti-cancer therapies","volume":"38","author":"Seebacher","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pacini, L., Jenks, A.D., Lima, N.C., and Huang, P.H. (2021). Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer. Cells, 10.","DOI":"10.3390\/cells10051154"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","article-title":"Safety and Tolerability of c-MET Inhibitors in Cancer","volume":"42","author":"Puccini","year":"2019","journal-title":"Drug Saf."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cascetta, P., Sforza, V., Manzo, A., Carillio, G., Palumbo, G., Esposito, G., Montanino, A., Costanzo, R., Sandomenico, C., and De Cecio, R. (2021). RET Inhibitors in Non-Small-Cell Lung Cancer. Cancers, 13.","DOI":"10.3390\/cancers13174415"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_18","unstructured":"ZYKADIA (Ceritinib) (2022, February 07). Prescribing Information, Available online: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205755s000lbl.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.canlet.2016.02.009","article-title":"Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer","volume":"374","author":"Kang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14737140.2019.1643239","article-title":"Capmatinib for the treatment of non-small cell lung cancer","volume":"19","author":"Vansteenkiste","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","unstructured":"NERLYNX (Neratinib) (2022, February 15). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208051s005s006lbl.pdf."},{"key":"ref_26","unstructured":"TUKYSA (Tucatinib) (2022, February 15). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213411s000lbl.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With \u22652 HER2-Directed Regimens: Phase III NALA Trial","volume":"38","author":"Saura","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","article-title":"Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models","volume":"19","author":"Kulukian","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_33","unstructured":"PEMAZYRE (Pemigatinib) (2022, February 15). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213736s000lbl.pdf."},{"key":"ref_34","unstructured":"TRUSELTIQ (Infigratinib) (2022, February 15). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214622s000lbl.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1479-5876-11-15","article-title":"Vascularity of primary and metastatic renal cell carcinoma specimens","volume":"11","author":"Aziz","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11912-015-0451-3","article-title":"Tivozanib: Status of Development","volume":"17","author":"Jamil","year":"2015","journal-title":"Curr. Oncol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): A phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_38","unstructured":"FOTIVDA (Tivozanib) (2022, February 17). Prescribing Information. Available online: https:\/\/www.aveooncology.com\/fotivdapi.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s40265-021-01632-9","article-title":"Mobocertinib: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","article-title":"Infigratinib: First Approval","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"key":"ref_41","unstructured":"European Medicines Agency (2022, February 09). Infigratinib for the Treatment of Cholangiocarcinoma. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/20\/2329-public-summary-opinion-orphan-designation-infigratinib-treatment-cholangiocarcinoma_en.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s40265-017-0825-y","article-title":"Tivozanib: First Global Approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"ref_43","unstructured":"European Medicines Agency (2022, February 09). Fotivda: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fotivda-epar-product-information_en.pdf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","article-title":"Tepotinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_46","unstructured":"European Medicines Agency (2022, February 09). Gavreto: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/gavreto-epar-medicine-overview_en.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40265-020-01347-3","article-title":"Capmatinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_49","unstructured":"European Medicines Agency (2022, February 09). Pemazyre: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pemazyre-epar-product-information_en.pdf."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40265-020-01340-w","article-title":"Tucatinib: First Approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"ref_51","unstructured":"European Medicines Agency (2022, February 09). Tukysa: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tukysa-epar-medicine-overview_en.pdf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: First Global Approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"ref_53","unstructured":"European Medicines Agency (2022, February 09). Nerlynx: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/nerlynx-epar-medicine-overview_en.pdf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: First Global Approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"ref_55","unstructured":"European Medicines Agency (2022, February 09). Tagrisso: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tagrisso-epar-medicine-overview_en.pdf."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-014-0251-3","article-title":"Ceritinib: First Global Approval","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"ref_57","unstructured":"European Medicines Agency (2022, February 09). Zykadia: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/zykadia-epar-medicine-overview_en.pdf."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"126637","DOI":"10.1016\/j.bmcl.2019.126637","article-title":"Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015\u20132019)","volume":"29","author":"Lallena","year":"2019","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fonc.2018.00608","article-title":"CDK 4\/6 Inhibitors as Single Agent in Advanced Solid Tumors","volume":"8","author":"Schelttini","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor\u2013Positive, HER2-Negative Metastatic Breast Cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-16-0493","article-title":"FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer","volume":"22","author":"Walker","year":"2016","journal-title":"Clin Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-017-4518-8","article-title":"Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2\u2212 advanced breast cancer in the randomized MONALEESA-2 trial","volume":"168","author":"Petrakova","year":"2018","journal-title":"Breast Cancer Res. Treat"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and Safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1124\/dmd.114.062745","article-title":"Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft","volume":"43","author":"Raub","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor\u2013Positive Breast Cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-017-0840-z","article-title":"Abemaciclib: First Global Approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"ref_68","unstructured":"European Medicines Agency (2022, February 09). Verzenios: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/verzenios-epar-medicine-overview_en.pdf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40265-017-0742-0","article-title":"Ribociclib: First Global Approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"ref_70","unstructured":"European Medicines Agency (2022, February 09). Kisqali: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/kisqali-epar-medicine-overview_en.pdf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-015-0379-9","article-title":"Palbociclib: First Global Approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"ref_72","unstructured":"European Medicines Agency (2022, February 09). Ibrance: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ibrance-epar-product-information_en.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2174\/138955708786369591","article-title":"Recent advances in the development of multi-kinase inhibitors","volume":"8","author":"Krug","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: Multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a Pan\u2013TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.2147\/OTT.S198945","article-title":"Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","article-title":"Erdafitinib: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_80","first-page":"391","article-title":"Dabrafenib and its potential for the treatment of metastatic melanoma","volume":"6","author":"Menzies","year":"2012","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9081","DOI":"10.2147\/OTT.S171693","article-title":"Encorafenib\/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: Design, development, and potential place in therapy","volume":"11","author":"Sun","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_84","first-page":"1290","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"383","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med. 2020, 382, 1430\u20131442; Erratum in N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/13543784.2012.684752","article-title":"Regorafenib for cancer","volume":"21","author":"Strumberg","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and Trametinib Treatment in Patients with Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2019.1538796","article-title":"Larotrectinib for the treatment of TRK fusion solid tumors","volume":"19","author":"Laetsch","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-3-319-91442-8_10","article-title":"Larotrectinib (LOXO-101)","volume":"211","author":"Berger","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: Role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.2147\/CMAR.S216605","article-title":"Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date","volume":"12","author":"Chau","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1517\/13543784.17.5.741","article-title":"Axitinib for renal cell carcinoma","volume":"17","author":"Sonpavde","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40265-020-01348-2","article-title":"Ripretinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_100","unstructured":"European Medicines Agency (2022, February 09). Qinlock: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/qinlock-epar-medicine-overview_en.pdf."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40265-020-01343-7","article-title":"Selpercatinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_102","unstructured":"European Medicines Agency (2022, February 09). Retsevmo: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/retsevmo-epar-medicine-overview_en.pdf."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40265-020-01331-x","article-title":"Selumetinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_104","unstructured":"European Medicines Agency (2022, February 09). Koselugo: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/koselugo-epar-medicine-overview_en.pdf."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","article-title":"Avapritinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_106","unstructured":"European Medicines Agency (2022, February 09). Ayvakyt: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ayvakyt-epar-medicine-overview_en.pdf."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: First Global Approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"ref_108","unstructured":"European Medicines Agency (2022, February 09). Rozlytrek: EPAR\u2014Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/rozlytrek-epar-overview_en.pdf."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: First Approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"ref_110","unstructured":"European Medicines Agency (2022, February 09). Refusal of the Marketing Authorisation for Turalio (Pexidartinib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-answers-refusal-marketing-authorisation-turalio-pexidartinib_en.pdf."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: First Global Approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"ref_112","unstructured":"European Medicines Agency (2022, February 09). Vitrakvi: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vitrakvi-epar-product-information_en.pdf."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","article-title":"Lorlatinib: First Global Approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"ref_114","unstructured":"European Medicines Agency (2022, February 09). Lorviqua: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lorviqua-epar-medicine-overview_en.pdf."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-018-1028-x","article-title":"Dacomitinib: First Global Approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"ref_116","unstructured":"European Medicines Agency (2022, February 09). Vizimpro: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vizimpro-epar-product-information_en.pdf."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","article-title":"Encorafenib and Binimetinib: First Global Approvals","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"ref_118","unstructured":"European Medicines Agency (2022, February 09). Braftovi: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/braftovi-epar-medicine-overview_en.pdf."},{"key":"ref_119","unstructured":"European Medicines Agency (2022, February 09). Mektovi: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mektovi-epar-medicine-overview_en.pdf."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-017-0776-3","article-title":"Brigatinib: First Global Approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref_121","unstructured":"European Medicines Agency (2022, February 09). Alunbrig: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alunbrig-epar-product-information_en.pdf."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-018-0952-0","article-title":"Alectinib: A Review in Advanced, ALK-Positive NSCLC","volume":"78","author":"Paik","year":"2018","journal-title":"Drugs"},{"key":"ref_123","unstructured":"European Medicines Agency (2022, February 09). Alecensa: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/alecensa-epar-summary-public_en.pdf."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s40265-015-0477-8","article-title":"Cobimetinib: First Global Approval","volume":"75","year":"2015","journal-title":"Drugs"},{"key":"ref_125","unstructured":"European Medicines Agency (2022, February 09). Cotellic: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/cotellic-epar-summary-public_en.pdf."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40265-015-0383-0","article-title":"Lenvatinib: First Global Approval","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"ref_127","unstructured":"European Medicines Agency (2022, February 09). Lenvima: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lenvima-epar-medicine-overview_en.pdf."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: First Global Approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"ref_129","unstructured":"European Medicines Agency (2022, February 09). Giotrif: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/giotrif-epar-summary-public_en.pdf."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-013-0096-1","article-title":"Trametinib: First Global Approval","volume":"73","author":"Wright","year":"2013","journal-title":"Drugs"},{"key":"ref_131","unstructured":"European Medicines Agency (2022, February 11). Mekinist: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mekinist-epar-medicine-overview_en.pdf."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s40265-013-0095-2","article-title":"Dabrafenib: First Global Approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"ref_133","unstructured":"European Medicines Agency (2022, February 11). Tafinlar: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tafinlar-epar-medicine-overview_en.pdf."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1078-0432.CCR-16-1073","article-title":"Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_135","unstructured":"CABOMETYX (Cabozantinib) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208692s003lbl.pdf."},{"key":"ref_136","unstructured":"European Medicines Agency (2022, February 11). Cabometyx: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/cabometyx-epar-medicine-overview_en.pdf."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1871520614666140902153840","article-title":"A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: Cabozantinib","volume":"15","author":"Roy","year":"2015","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_138","unstructured":"COMETRIQ (Cabozantinib) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203756lbl.pdf."},{"key":"ref_139","unstructured":"European Medicines Agency (2022, February 11). Cometriq: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/cometriq-epar-summary-public_en.pdf."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-3-642-54490-3_10","article-title":"Regorafenib","volume":"201","author":"Ettrich","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"ref_141","unstructured":"STIVARGA (Regorafenib) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203085lbl.pdf."},{"key":"ref_142","unstructured":"European Medicines Agency (2022, February 11). Stivarga: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/stivarga-epar-summary-public_en.pdf."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.2147\/DDDT.S109640","article-title":"Axitinib in the treatment of renal cell carcinoma: Design, development, and place in therapy","volume":"11","author":"Bellesoeur","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_144","unstructured":"INLYTA (Axitinib) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202324lbl.pdf."},{"key":"ref_145","unstructured":"European Medicines Agency (2022, February 11). Inlyta: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/inlyta-epar-summary-public_en.pdf."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrd3600","article-title":"Crizotinib","volume":"10","author":"Shaw","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_147","unstructured":"XALKORI (Crizotinib) (2022, January 23). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202570s030lbl.pdf."},{"key":"ref_148","unstructured":"European Medicines Agency (2022, February 11). Xalkori: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xalkori-epar-summary-public_en.pdf."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nrd3579","article-title":"Vemurafenib","volume":"10","author":"Flaherty","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_150","unstructured":"ZELBORAF (Vemurafenib) (2022, January 23). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202429s012lbl.pdf."},{"key":"ref_151","unstructured":"European Medicines Agency (2022, February 11). Zelboraf: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/zelboraf-epar-summary-public_en.pdf."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2165\/11209300-000000000-00000","article-title":"Vandetanib","volume":"72","author":"Frampton","year":"2012","journal-title":"Drugs"},{"key":"ref_153","unstructured":"European Medicines Agency (2022, February 11). Caprelsa: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/caprelsa-epar-summary-public_en.pdf."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1358\/dof.2007.032.06.1107995","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs","volume":"32","author":"Verheijen","year":"2007","journal-title":"Drugs Future."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1038\/sj.onc.1203871","article-title":"A specific function for phosphatidylinositol 3-kinase \u03b1 (p85\u03b1-p110\u03b1) in cell survival and for phosphatidylinositol 3-kinase \u03b2 (p85\u03b1-p110\u03b2) in de novo DNA synthesis of human colon carcinoma cells","volume":"19","author":"Chapuis","year":"2000","journal-title":"Oncogene"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase alpha-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: Results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_158","unstructured":"PIQRAY (Alpelisib) (2022, January 23). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212526s000lbl.pdf."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/j.1349-7006.2008.00891.x","article-title":"Phosphatidylinositol 3-kinase inhibitors: Promising drug candidates for cancer therapy","volume":"99","author":"Kong","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref_161","unstructured":"European Medicines Agency (2022, February 11). Piqray: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/piqray-epar-medicine-overview_en.pdf."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","article-title":"The current understanding of KRAS protein structure and dynamics","volume":"18","author":"Pantsar","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/d41586-019-03242-8","article-title":"Small molecule combats cancer-causing KRAS protein at last","volume":"575","author":"Herbst","year":"2019","journal-title":"Nature."},{"key":"ref_164","unstructured":"LUMAKRAS (Sotorasib) (2022, February 13). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214665s000lbl.pdf."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"113816","DOI":"10.1016\/j.ejmech.2021.113816","article-title":"Targeting mutated GTPase KRAS in tumor therapies","volume":"226","author":"Fan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Liu, J., Kang, R., and Tang, D. (2021). The KRAS-G12C inhibitor: Activity and resistance. Cancer Gene Ther.","DOI":"10.1038\/s41417-021-00383-9"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: First Approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Ganellin, C., Roberts, S., and Jefferis, R. (2013). Chapter 1\u2013Introduction to enzymes, receptors and the action of small molecule drugs. Introduction to Biological and Small Molecule Drug Research and Development, Elsevier.","DOI":"10.1016\/B978-0-12-397176-0.00001-7"},{"key":"ref_170","first-page":"23","article-title":"Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer","volume":"38","author":"Goldberg","year":"2013","journal-title":"P&T"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-13-2134","article-title":"Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary","volume":"19","author":"Kluetz","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdw067","article-title":"A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)","volume":"27","author":"Bonnefoi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","article-title":"Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond","volume":"20","author":"Boussios","year":"2020","journal-title":"Drugs R&D"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.2147\/CMAR.S227033","article-title":"PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date","volume":"12","author":"Nizialek","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA Topoisomerases: Structure, Function, and Mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"ref_179","unstructured":"Irinotecan Hydrochloride NDA #020571 (2022, February 24). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020571."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","article-title":"Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer","volume":"21","author":"Fujita","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.2147\/OTT.S105587","article-title":"Onivyde for the therapy of multiple solid tumors","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_182","first-page":"536","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial","volume":"387","author":"Li","year":"2016","journal-title":"Lancet 2016, 387, 545\u2013557; Erratum in Lancet"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: From biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_185","unstructured":"TAZVERIK (Tazemetostat) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213400s000lbl.pdf."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_188","unstructured":"European Medicines Agency (2022, February 11). Talzenna: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/talzenna-epar-medicine-overview_en.pdf."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40265-017-0752-y","article-title":"Niraparib: First global approval","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"ref_190","unstructured":"European Medicines Agency (2022, February 11). Zejula: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/zejula-epar-medicine-overview_en.pdf."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-017-0716-2","article-title":"Rucaparib: First global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"ref_192","unstructured":"European Medicines Agency (2022, February 11). Rubraca: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/rubraca-epar-medicine-overview_en.pdf."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"104398","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_194","unstructured":"ONIVYDE (Irinotecan Liposome Injection) (2022, January 23). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207793lbl.pdf."},{"key":"ref_195","unstructured":"European Medicines Agency (2022, February 11). Onivyde: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/onivyde-epar-medicine-overview_en.pdf."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-015-0345-6","article-title":"Olaparib: First Global Approval","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2217\/fon.14.313","article-title":"Olaparib: An oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer","volume":"11","author":"Gunderson","year":"2015","journal-title":"Future Oncol."},{"key":"ref_198","unstructured":"European Medicines Agency (2022, February 11). Lynparza: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lynparza-epar-medicine-overview_en.pdf."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14656566.2013.745852","article-title":"Abiraterone acetate for the treatment of prostate cancer","volume":"14","author":"Ryan","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_200","unstructured":"ZYTIGA (Abiraterone Acetate) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202379lbl.pdf."},{"key":"ref_201","unstructured":"European Medicines Agency (2022, February 11). Zytiga: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/zytiga-epar-summary-public_en.pdf."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Casem, M. (2016). Chapter 9\u2014Endocytosis. Problem Sets in Biological and Biomedical Sciences. Case Studies in Cell Biology, Academic Press.","DOI":"10.1016\/B978-0-12-801394-6.00009-9"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14656566.2020.1713094","article-title":"An evaluation of glasdegib for the treatment of acute myelogenous leukemia","volume":"21","author":"Thomas","year":"2020","journal-title":"Expert Opin. Pharma-cother."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2009.03.007","article-title":"Mechanisms of Hedgehog pathway activation in cancer and implications for therapy","volume":"30","author":"Scales","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/ncomms5355","article-title":"Structural basis for smoothened receptor modulation and chemoresistance to anticancer drugs","volume":"5","author":"Wang","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0976-500X.107628","article-title":"The dawn of hedgehog inhibitors: Vismodegib","volume":"4","author":"Sandhiya","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/OTT.S130910","article-title":"Sonidegib: Mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas","volume":"10","author":"Jain","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/jdv.16230","article-title":"Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: A joint expert opinion","volume":"34","author":"Dummer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","article-title":"Androgen Receptor (AR) Coregulators: An Overview","volume":"23","author":"Heinlein","year":"2002","journal-title":"Endocr. Rev."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_213","unstructured":"XTANDI (Enzalutamide) (2022, January 23). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203415s014lbl.pdf."},{"key":"ref_214","unstructured":"ERLEADA (Apalutamide) (2022, January 23). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210951s001lbl.pdf."},{"key":"ref_215","unstructured":"NUBEQA (Darolutamide) (2022, January 23). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0140-6736(01)06797-6","article-title":"Gonadotropin-releasing-hormone-receptor antagonists","volume":"358","author":"Huirne","year":"2001","journal-title":"Lancet"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1210\/edrv.18.2.0295","article-title":"Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor","volume":"18","author":"Sealfon","year":"1997","journal-title":"Endocr. Rev."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-019-01105-0","article-title":"Relugolix: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s40265-019-01212-y","article-title":"Darolutamide: First Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref_221","unstructured":"European Medicines Agency (2022, February 11). Nubeqa: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/nubeqa-epar-medicine-overview_en.pdf."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40265-018-0900-z","article-title":"Apalutamide: First Global Approval","volume":"78","year":"2018","journal-title":"Drugs"},{"key":"ref_223","unstructured":"European Medicines Agency (2022, February 11). Erleada: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/erleada-epar-medicine-overview_en.pdf."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-015-0458-y","article-title":"Sonidegib: First Global Approval","volume":"75","author":"Burness","year":"2015","journal-title":"Drugs"},{"key":"ref_225","unstructured":"European Medicines Agency (2022, February 11). Odomzo: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/odomzo-epar-summary-public_en.pdf."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1158\/1078-0432.CCR-13-1763","article-title":"Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary","volume":"19","author":"Ning","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_227","unstructured":"XTANDI (Enzalutamide) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203415lbl.pdf."},{"key":"ref_228","unstructured":"European Medicines Agency (2022, February 11). Xtandi: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xtandi-epar-medicine-overview_en.pdf."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-12-1956","article-title":"Food and Drug Administration approval: Vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma","volume":"19","author":"Axelson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_230","unstructured":"ERIVEDGE (Vismodegib) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203388lbl.pdf."},{"key":"ref_231","unstructured":"European Medicines Agency (2022, February 11). Erivedge: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/erivedge-epar-summary-public_en.pdf."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1021\/bi960306b","article-title":"DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ectainiascidin 743, a potent antitumor compound from the caribbean tunicate ecteinascidia turbinata","volume":"35","author":"Pommier","year":"1996","journal-title":"Biochemistry"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1476-5381.2010.00945.x","article-title":"PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity","volume":"161","author":"Leal","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): A unique mechanism of action","volume":"9","author":"Galmarini","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells","volume":"15","author":"Robles","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"e1656502","DOI":"10.1080\/2162402X.2019.1656502","article-title":"Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity","volume":"8","author":"Xie","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00280-021-04246-w","article-title":"Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma","volume":"87","author":"Shabsigh","year":"2021","journal-title":"Cancer Chemother. Pharmacol"},{"key":"ref_240","unstructured":"MITOMYCIN ANDA #064106 (2022, February 22). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=064106."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00003495-200666030-00005","article-title":"Mitomycin","volume":"66","author":"Abraham","year":"2006","journal-title":"Drugs"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"120954","DOI":"10.1016\/j.ijpharm.2021.120954","article-title":"Thermo-responsive hydrogels for cancer local therapy: Challenges and state-of-art","volume":"606","author":"Rafael","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40265-020-01374-0","article-title":"Lurbinectedin: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_244","unstructured":"JELMYTO (Mitomycin) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/211728s000lbl.pdf."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-17-0898","article-title":"FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen","volume":"23","author":"Barone","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_246","unstructured":"YONDELIS (Trabectedin) (2022, January 31). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207953s000lbl.pdf."},{"key":"ref_247","unstructured":"European Medicines Agency (2022, February 11). Yondelis: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/yondelis-epar-summary-public_en.pdf."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","article-title":"Targeted radionuclide therapy in combined-modality regimens","volume":"18","author":"Gill","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Jimenez, C., Erwin, W., and Chasen, B. (2019). Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine. Cancers, 11.","DOI":"10.3390\/cancers11071018"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13139-018-0523-z","article-title":"Current Consensus on I-131 MIBG Therapy","volume":"52","author":"Kayano","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Kopka, K. (2019). Lutathera\u00ae: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals, 12.","DOI":"10.3390\/ph12030114"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/071294b0","article-title":"A New Radio-active Product from Actinium","volume":"71","author":"Godlewski","year":"1905","journal-title":"Nature"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14786440509463342","article-title":"Actinium and its successive products","volume":"10","author":"Godlewski","year":"1905","journal-title":"Philos. Mag. Ser. 6"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40265-014-0198-4","article-title":"Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases","volume":"74","author":"Shirley","year":"2014","journal-title":"Drugs"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2147\/DDDT.S122417","article-title":"Radium 223 dichloride for prostate cancer treatment","volume":"11","author":"Deshayes","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_257","unstructured":"AZEDRA (Iobenguane I 131) (2022, January 25). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209607s000lbl.pdf."},{"key":"ref_258","unstructured":"European Medicines Agency (2022, February 11). List of Nationally Authorized Medicinal Products. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/iodine-131i-iobenguane-list-nationally-authorised-medicinal-products-psusa\/00001764\/201505_en.pdf."},{"key":"ref_259","unstructured":"LUTATHERA (Lutetium Lu 177 Dotatate) (2022, February 06). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208700s000lbl.pdf."},{"key":"ref_260","unstructured":"European Medicines Agency (2022, February 11). Lutathera: EPAR\u2014Summary for the Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lutathera-epar-summary-public_en.pdf."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-13-2665","article-title":"Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary","volume":"20","author":"Kluetz","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_262","unstructured":"European Medicines Agency (2022, February 11). Xofigo: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xofigo-epar-medicine-overview_en.pdf."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40005-016-0286-4","article-title":"Rationale and strategies for formulation development of oral fixed dose combination drug products","volume":"46","author":"Moon","year":"2016","journal-title":"J. Pharm. Investig."},{"key":"ref_264","unstructured":"TRIFLURIDINE NDA #018299 (2022, February 24). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=018299."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1535-6108(04)00080-7","article-title":"Thymidylate synthase as an oncogene: A novel role for an essential DNA synthesis enzyme","volume":"5","author":"Rahman","year":"2004","journal-title":"Cancer Cell."},{"key":"ref_266","first-page":"314","article-title":"Trifluridine\/Tipiracil (Lonsurf) for the Treatment of Metastatic Colorectal Cancer","volume":"41","author":"Kish","year":"2016","journal-title":"P&T"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003495-198223050-00001","article-title":"Trifluridine: A Review of its Antiviral Activity and Therapeutic Use in the Topical Treatment of Viral Eye Infections","volume":"23","author":"Carmine","year":"1982","journal-title":"Drugs"},{"key":"ref_268","unstructured":"LONSURF (Trifluridine and Tipiracil) (2022, January 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/207981s008lbl.pdf."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/14740338.2018.1475557","article-title":"The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer","volume":"17","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_270","unstructured":"European Medicines Agency (2022, February 11). Lonsurf: EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lonsurf-epar-medicine-overview_en.pdf."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chembiol.2019.10.013","article-title":"Development and Characterization of a Wee1 Kinase Degrader","volume":"27","author":"Li","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Rothweiler, E.M., Stefaniak, J., Ward, J.A., Rogers, C., Balikci, E., and Huber, K.V.M. (2022). A chemical biology toolbox to investigate in-cell target engagement and specificity of PRMT5-inhibitors. bioRxiv.","DOI":"10.1101\/2022.01.20.477145"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","article-title":"GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer","volume":"64","author":"Liang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3892\/ijo.2015.3306","article-title":"Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)","volume":"48","author":"Nitulescu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jcb.24787","article-title":"ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2","volume":"115","author":"Wang","year":"2014","journal-title":"J. Cell. Biochem."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lungcan.2021.07.005","article-title":"On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma","volume":"160","author":"Lindsay","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40164-019-0149-6","article-title":"Targeted and novel therapy in advanced gastric cancer","volume":"8","author":"Selim","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_279","unstructured":"(2022, March 26). ClinicalTrials.gov, Identifier: NCT04676516, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04676516?term=GSK3326595&phase=1&draw=2&rank=1."},{"key":"ref_280","unstructured":"Kummar, S., Li, S., Reiss, K., Ford, J.M., Mitchell, E.P., Zwiebel, J.A., Takebe, N., Gray, R.J., McShane, L.M., and Rubinstein, L.V. (April, January 29). NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations. Proceedings of the American Association for Cancer Research Annual Meeting, Atlanta, PA, USA."},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Sochacka-\u0106wik\u0142a, A., M\u0105czy\u0144ski, M., and Regiec, A. (2022). FDA-Approved Drugs for Hematological Malignancies\u2014The Last Decade Review. Cancers, 14.","DOI":"10.3390\/cancers14010087"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14737140.2017.1344553","article-title":"Cabozantinib for the treatment of kidney cancer","volume":"17","author":"Abdelaziz","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/jm401375q","article-title":"Data-mining for sulfur and fluorine: An evaluation of pharmaceuticals to reveal opportunities for drug design and discovery","volume":"57","author":"Ilardi","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Mendez, L., Henriquez, G., Sirimulla, S., and Narayan, M. (2017). Looking Back, Looking Forward at Halogen Bonding in Drug Discovery. Molecules, 22.","DOI":"10.3390\/molecules22091397"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"12290","DOI":"10.1021\/acs.jmedchem.0c00530","article-title":"Amide bond bioisosteres: Strategies, synthesis, and successes","volume":"63","author":"Kumari","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1021\/acs.jmedchem.9b01541","article-title":"Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry","volume":"63","author":"Ghosh","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00316585","article-title":"Studies on the mechanism of acute toxicity of nitriles in mice","volume":"55","author":"Tanii","year":"1984","journal-title":"Arch. Toxicol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"7902","DOI":"10.1021\/jm100762r","article-title":"Nitrile-containing pharmaceuticals: Efficacious roles of the nitrile pharmacophore","volume":"53","author":"Fleming","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1039\/D1MD00131K","article-title":"Nitrile-containing pharmaceuticals: Target, mechanism of action, and their SAR studies","volume":"12","author":"Wang","year":"2021","journal-title":"RSC Med. Chem."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"694363","DOI":"10.3389\/fcell.2021.694363","article-title":"Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges","volume":"9","author":"Sun","year":"2021","journal-title":"Front Cell Dev. Biol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/7\/2259\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:47:11Z","timestamp":1760136431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/7\/2259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":291,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["molecules27072259"],"URL":"https:\/\/doi.org\/10.3390\/molecules27072259","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}